MacroGenics Stock Price, News & Analysis (NASDAQ:MGNX)

$19.27 0.25 (1.31 %)
(As of 12/15/2017 04:00 PM ET)
Previous Close$19.27
Today's Range$18.86 - $19.42
52-Week Range$14.36 - $22.31
Volume476,126 shs
Average Volume268,668 shs
Market Capitalization$700.37 million
P/E RatioN/A
Dividend YieldN/A
Beta2.73

About MacroGenics (NASDAQ:MGNX)

MacroGenics logoMacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created using its technology platforms. Its clinical product candidate, margetuximab, has been enhanced using its Fc Optimization platform. The Company is also developing several product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. The Company's product candidates also include enoblituzumab and MGD009, MGC018, MGD006 (flotetuzumab), MGD007, MGD011 (duvortuxizumab), PF-06671008 and MGD010.

Receive MGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MGNX
CUSIPN/A
Phone301-251-5172

Debt

Debt-to-Equity RatioN/A
Current Ratio6.46%
Quick Ratio6.46%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$91.88 million
Price / Sales7.72
Cash FlowN/A
Price / CashN/A
Book Value$7.71 per share
Price / Book2.50

Profitability

Trailing EPS($4.50)
Net Income$-58,520,000.00
Net Margins-1,526.55%
Return on Equity-69.31%
Return on Assets-58.09%

Miscellaneous

Employees318
Outstanding Shares36,820,000

MacroGenics (NASDAQ:MGNX) Frequently Asked Questions

What is MacroGenics' stock symbol?

MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."

How were MacroGenics' earnings last quarter?

MacroGenics Inc (NASDAQ:MGNX) released its quarterly earnings data on Wednesday, November, 8th. The biopharmaceutical company reported ($1.28) EPS for the quarter, missing the Zacks' consensus estimate of ($1.09) by $0.19. The biopharmaceutical company had revenue of $1.70 million for the quarter, compared to the consensus estimate of $5.50 million. MacroGenics had a negative return on equity of 69.31% and a negative net margin of 1,526.55%. The company's revenue for the quarter was down 48.5% compared to the same quarter last year. During the same period last year, the firm earned ($0.97) earnings per share. View MacroGenics' Earnings History.

When will MacroGenics make its next earnings announcement?

MacroGenics is scheduled to release their next quarterly earnings announcement on Monday, February, 26th 2018. View Earnings Estimates for MacroGenics.

Where is MacroGenics' stock going? Where will MacroGenics' stock price be in 2017?

11 brokers have issued 1 year target prices for MacroGenics' shares. Their forecasts range from $21.00 to $44.00. On average, they anticipate MacroGenics' stock price to reach $31.33 in the next year. View Analyst Ratings for MacroGenics.

What are Wall Street analysts saying about MacroGenics stock?

Here are some recent quotes from research analysts about MacroGenics stock:

  • 1. According to Zacks Investment Research, "MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. " (10/10/2017)
  • 2. BTIG Research analysts commented, "Based upon the 4Q16 earnings call hosted last week and our follow-up conversation with management, we present an outline of expected activities during 2017. The majority of the MGNX portfolio will be entering or expanding Phase 1 studies during 2017, which will weigh potential clinical catalysts towards 2H2017 and early 2018. The most significant identified clinical read-out during 2017 will likely be the futility analysis from the Margetuximab pivotal study. We reiterate our Buy Rating but lower our Price Target to $28 from $35 as we push out Margetuximab sales expectations until 2021. A summary of events for 2017 is charted on Page 2 of this report." (3/6/2017)
  • 3. Cowen Inc analysts commented, "MGNX reported 4Q16 results and provided a pipeline update." (3/1/2017)
  • 4. Instinet analysts commented, "We are initiating coverage of MacroGenics with a Buy rating and $41 target price. We recommend accumulating MGNX shares in 2017, as we anticipate several data sets across programs, specifically for the company's B7-H3 franchise. We expect data cross multiple tumor types from ongoing basket trials of both enoblituzumab and bispecific counterpart MGD009 to define initial market opportunities that represent upside to current estimates." (3/1/2017)
  • 5. Stifel Nicolaus analysts commented, "Management's relatively quiet 4Q16 earnings announcement/call was expected following the comprehensive pipeline update provided at the December 2016 R&D Day. The specific timing and magnitude of incremental news flow from both wholly-owned and partnered programs throughout FY17 still remains a bit uncertain ' but we anticipate the finalization of dose and administration schedules for a variety of DART programs to allow for the initiation of dose expansion cohorts in both FY17 and beyond. SOPHIA enrollment appears to remain on track and a newly-implemented trial amendment allowing for Kadcyla-na??ve patients should facilitate the pace of enrollment and eventually expand the addressable market opportunity. We continue to find valuation attractive here. Reduced target price of $42 (previously $51) reflects higher FY17 and forward-year OpEx ' coupled with reduced longer-term collaborative revenue estimates." (3/1/2017)

Who are some of MacroGenics' key competitors?

Who are MacroGenics' key executives?

MacroGenics' management team includes the folowing people:

  • Paulo F. Costa, Independent Chairman of the Board
  • Scott Koenig M.D., Ph.D., President, Chief Executive Officer, Director
  • James Karrels MBA, Chief Financial Officer, Senior Vice President, Secretary
  • Ezio Bonvini M.D., Senior Vice President - Research, Chief Scientific Officer
  • Atul Saran, Senior Vice President, General Counsel
  • Eric Risser, Senior Vice President - Business Development and Portfolio Management and Chief Business Officer
  • Thomas Spitznagel Ph.D., Senior Vice President - Bio Pharmaceutical Development and Manufacturing
  • Jon Wigginton, Senior Vice President - Clinical Development and Chief Medical Officer
  • Lynn Cilinski, Vice President, Controller, Treasurer
  • Jay P. Siegel M.D., Director
  • , Bio & Compensation - 

Who owns MacroGenics stock?

MacroGenics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Point72 Asset Management L.P. (3.21%), Pinnacle Associates Ltd. (2.29%), Hood River Capital Management LLC (1.60%), Emerald Advisers Inc. PA (1.21%), Dimensional Fund Advisors LP (0.77%) and DekaBank Deutsche Girozentrale (0.62%). Company insiders that own MacroGenics stock include Jon Marc Wigginton, Lynn Cilinski and Paulo F Costa. View Institutional Ownership Trends for MacroGenics.

Who sold MacroGenics stock? Who is selling MacroGenics stock?

MacroGenics' stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A., Jennison Associates LLC, Highbridge Capital Management LLC, Emerald Advisers Inc. PA, California State Teachers Retirement System and Stifel Financial Corp. View Insider Buying and Selling for MacroGenics.

Who bought MacroGenics stock? Who is buying MacroGenics stock?

MacroGenics' stock was purchased by a variety of institutional investors in the last quarter, including Pinnacle Associates Ltd., Sphera Funds Management LTD., Dimensional Fund Advisors LP, Point72 Asset Management L.P., Granite Point Capital Management L.P., Citadel Advisors LLC, Tocqueville Asset Management L.P. and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for MacroGenics.

How do I buy MacroGenics stock?

Shares of MacroGenics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MacroGenics' stock price today?

One share of MacroGenics stock can currently be purchased for approximately $19.27.

How big of a company is MacroGenics?

MacroGenics has a market capitalization of $700.37 million and generates $91.88 million in revenue each year. The biopharmaceutical company earns $-58,520,000.00 in net income (profit) each year or ($4.50) on an earnings per share basis. MacroGenics employs 318 workers across the globe.

How can I contact MacroGenics?

MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company can be reached via phone at 301-251-5172.


MarketBeat Community Rating for MacroGenics (MGNX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  179 (Vote Outperform)
Underperform Votes:  156 (Vote Underperform)
Total Votes:  335
MarketBeat's community ratings are surveys of what our community members think about MacroGenics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

MacroGenics (NASDAQ:MGNX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.822.852.852.86
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $31.33$32.90$33.10$35.27
Price Target Upside: 67.47% upside80.27% upside81.67% upside86.43% upside

MacroGenics (NASDAQ:MGNX) Consensus Price Target History

Price Target History for MacroGenics (NASDAQ:MGNX)

MacroGenics (NASDAQ:MGNX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/11/2017Raymond James FinancialReiterated RatingBuyMediumView Rating Details
11/10/2017CitigroupBoost Price TargetNeutral$18.00 -> $22.00N/AView Rating Details
10/25/2017CowenReiterated RatingBuyN/AView Rating Details
9/12/2017Stifel NicolausReiterated RatingBuy$34.00HighView Rating Details
9/11/2017WedbushReiterated RatingOutperform$44.00HighView Rating Details
9/1/2017SunTrust BanksReiterated RatingBuy$26.00HighView Rating Details
8/7/2017Morgan StanleyLower Price TargetEqual Weight$22.00 -> $21.00LowView Rating Details
3/6/2017BTIG ResearchReiterated RatingBuy$35.00 -> $28.00N/AView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$41.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
3/1/2017Roth CapitalSet Price TargetBuy$40.00N/AView Rating Details
6/14/2016OppenheimerReiterated RatingBuyN/AView Rating Details
5/19/2016Leerink SwannReiterated RatingOutperform$47.00N/AView Rating Details
2/18/2016Janney Montgomery ScottInitiated CoverageBuy$36.00N/AView Rating Details
(Data available from 12/16/2015 forward)

Earnings

MacroGenics (NASDAQ:MGNX) Earnings History and Estimates Chart

Earnings by Quarter for MacroGenics (NASDAQ:MGNX)

MacroGenics (NASDAQ MGNX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/26/2018$2.62N/AView Earnings Details
11/8/2017Q3 2017($1.09)($1.28)$5.50 million$1.70 millionViewN/AView Earnings Details
8/2/2017Q2 2017($1.05)($1.14)$15.82 million$1.70 millionViewListenView Earnings Details
5/3/2017Q1 2017($0.99)($1.08)$5.88 million$2.06 millionViewListenView Earnings Details
2/28/2017Q416($0.86)($1.00)$10.65 million$5.00 millionViewListenView Earnings Details
11/2/2016Q316($0.80)($0.97)$12.45 million$3.30 millionViewN/AView Earnings Details
8/3/2016Q216($0.02)$1.12$27.22 million$80.67 millionViewN/AView Earnings Details
5/4/2016Q1($0.67)($0.88)$10.95 million$2.85 millionViewN/AView Earnings Details
8/5/2015Q2($0.44)($0.71)$13.88 million$6.72 millionViewN/AView Earnings Details
5/6/2015Q1 2015$0.87($0.58)$58.29 million$71.28 millionViewN/AView Earnings Details
3/3/2015Q4 2014($0.36)($0.69)$12.41 million$5.48 millionViewN/AView Earnings Details
11/11/2014Q3 2014($0.42)($0.14)$9.43 million$18.38 millionViewListenView Earnings Details
8/5/2014Q2 2014($0.29)($0.44)$11.22 million$9.22 millionViewN/AView Earnings Details
5/6/2014Q1 2014($0.09)($0.12)$18.00 million$14.72 millionViewN/AView Earnings Details
11/12/2013$0.15$0.01ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

MacroGenics (NASDAQ:MGNX) Earnings Estimates

2017 EPS Consensus Estimate: ($2.18)
2018 EPS Consensus Estimate: ($4.13)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($1.18)($0.83)($1.03)
Q2 20174($1.17)($0.83)($1.03)
Q3 20174($1.21)($0.86)($1.04)
Q4 20174($1.02)$2.99$0.92
Q1 20182($1.10)($0.97)($1.04)
Q2 20182($1.13)($0.88)($1.01)
Q3 20182($1.15)($0.91)($1.03)
Q4 20182($1.18)($0.93)($1.06)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for MacroGenics (NASDAQ:MGNX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

MacroGenics (NASDAQ MGNX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.30%
Institutional Ownership Percentage: 85.81%
Insider Trades by Quarter for MacroGenics (NASDAQ:MGNX)
Insider Trades by Quarter for MacroGenics (NASDAQ:MGNX)

MacroGenics (NASDAQ MGNX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/21/2017Jon Marc WiggintonSVPSell5,000$20.00$100,000.00View SEC Filing  
10/25/2017Jon Marc WiggintonSVPSell10,000$20.00$200,000.00View SEC Filing  
6/5/2017Jon Marc WiggintonSVPSell5,000$20.00$100,000.00View SEC Filing  
4/19/2017Jon Marc WiggintonSVPSell15,000$20.00$300,000.00View SEC Filing  
10/3/2016Jon Marc WiggintonCMOSell10,000$29.34$293,400.00View SEC Filing  
10/3/2016Lynn CilinskiVPSell6,231$29.28$182,443.68View SEC Filing  
8/1/2016Jon Marc WiggintonSVPSell20,000$30.78$615,600.00View SEC Filing  
7/1/2016Jon Marc WiggintonCMOSell5,000$27.22$136,100.00View SEC Filing  
7/1/2016Lynn CilinskiVPSell8,922$27.22$242,856.84View SEC Filing  
5/27/2016Lynn CilinskiVPSell5,000$25.00$125,000.00View SEC Filing  
3/3/2016Paulo F CostaDirectorBuy10,000$17.20$172,000.00View SEC Filing  
1/4/2016Jon Marc WiggintonSVPSell10,000$29.64$296,400.00View SEC Filing  
11/23/2015Lynn CilinskiVPSell6,921$35.00$242,235.00View SEC Filing  
11/16/2015Ezio BonviniVPSell3,117$31.44$97,998.48View SEC Filing  
10/15/2015Ezio BonviniVPSell6,233$25.21$157,133.93View SEC Filing  
10/1/2015Jon Marc WiggintonSVPSell5,000$21.11$105,550.00View SEC Filing  
7/10/2015Ezio BonviniVPSell2,400$38.09$91,416.00View SEC Filing  
7/1/2015Jon Marc WiggintonSVPSell5,000$37.15$185,750.00View SEC Filing  
7/1/2015Lynn CilinskiVPSell6,921$37.15$257,115.15View SEC Filing  
6/30/2015Ezio BonviniVPSell6,497$38.07$247,340.79View SEC Filing  
6/24/2015Ezio BonviniVPSell6,097$38.08$232,173.76View SEC Filing  
6/23/2015Ezio BonviniVPSell13,054$38.14$497,879.56View SEC Filing  
6/15/2015Ezio BonviniVPSell6,233$34.01$211,984.33View SEC Filing  
5/15/2015Ezio BonviniVPSell6,233$30.24$188,485.92View SEC Filing  
4/15/2015Ezio BonviniVPSell6,233$33.98$211,797.34View SEC Filing  
2/2/2015Jon Marc WiggintonSVPSell5,000$31.04$155,200.00View SEC Filing  
12/22/2014Kathryn E SteinSVPSell10,946$37.00$405,002.00View SEC Filing  
12/18/2014Eric Blasius RisserVPSell10,000$33.50$335,000.00View SEC Filing  
12/18/2014Kathryn E SteinSVPSell10,946$33.00$361,218.00View SEC Filing  
11/24/2014Eric Blasius RisserVPSell10,000$27.75$277,500.00View SEC Filing  
11/21/2014Kathryn E SteinVPSell10,946$27.00$295,542.00View SEC Filing  
11/17/2014Kathryn E SteinVPSell25,301$23.30$589,513.30View SEC Filing  
11/13/2014Eric Blasius RisserVPSell25,000$23.80$595,000.00View SEC Filing  
10/1/2014Jon Marc WiggintonVPSell5,000$20.48$102,400.00View SEC Filing  
9/2/2014Eric Blasius RisserVPSell8,316$20.89$173,721.24View SEC Filing  
8/18/2014Jon Marc WiggintonVPSell5,000$20.52$102,600.00View SEC Filing  
6/30/2014Eric Blasius RisserVPSell8,000$21.84$174,720.00View SEC Filing  
5/29/2014Kathryn E SteinVPSell10,946$19.75$216,183.50View SEC Filing  
2/18/2014Edward HurwitzDirectorSell308,513$36.50$11,260,724.50View SEC Filing  
10/16/2013Kenneth GalbraithDirectorBuy46,875$16.00$750,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

MacroGenics (NASDAQ MGNX) News Headlines

Source:
DateHeadline
MacroGenics, Inc. – Value Analysis (NASDAQ:MGNX) : December 14, 2017MacroGenics, Inc. – Value Analysis (NASDAQ:MGNX) : December 14, 2017
finance.yahoo.com - December 14 at 6:07 PM
Macrogenics (MGNX) Phase 1 Data for Flotetuzumab Presented ASHMacrogenics (MGNX) Phase 1 Data for Flotetuzumab Presented ASH
www.streetinsider.com - December 13 at 5:45 PM
Macrogenics (MGNX) Phase 1 Data for Flotetuzumab Presented ASH - StreetInsider.comMacrogenics (MGNX) Phase 1 Data for Flotetuzumab Presented ASH - StreetInsider.com
www.streetinsider.com - December 13 at 9:28 AM
MacroGenics, Inc. breached its 50 day moving average in a Bearish Manner : MGNX-US : December 13, 2017MacroGenics, Inc. breached its 50 day moving average in a Bearish Manner : MGNX-US : December 13, 2017
finance.yahoo.com - December 13 at 9:28 AM
MacroGenics (MGNX) Earns "Buy" Rating from Raymond James FinancialMacroGenics (MGNX) Earns "Buy" Rating from Raymond James Financial
www.americanbankingnews.com - December 12 at 9:28 AM
Phase 1 Data for Flotetuzumab, MacroGenics’ CD123 x CD3 DART® Molecule, Presented at 59th Annual ASH MeetingPhase 1 Data for Flotetuzumab, MacroGenics’ CD123 x CD3 DART® Molecule, Presented at 59th Annual ASH Meeting
finance.yahoo.com - December 11 at 5:48 PM
MacroGenics Announces Closing of MGA012 Global Collaboration and License Agreement with IncyteMacroGenics Announces Closing of MGA012 Global Collaboration and License Agreement with Incyte
finance.yahoo.com - December 5 at 5:30 PM
MacroGenics, Inc. (MGNX) Expected to Announce Quarterly Sales of $152.60 MillionMacroGenics, Inc. (MGNX) Expected to Announce Quarterly Sales of $152.60 Million
www.americanbankingnews.com - December 4 at 10:12 AM
MacroGenics (MGNX) Upgraded by ValuEngine to "Sell"MacroGenics (MGNX) Upgraded by ValuEngine to "Sell"
www.americanbankingnews.com - December 3 at 7:30 AM
Zacks: Analysts Expect MacroGenics, Inc. (MGNX) to Post $2.58 EPSZacks: Analysts Expect MacroGenics, Inc. (MGNX) to Post $2.58 EPS
www.americanbankingnews.com - December 2 at 1:38 PM
MacroGenics, Inc. (MGNX) Given Average Recommendation of "Buy" by BrokeragesMacroGenics, Inc. (MGNX) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - November 26 at 4:08 PM
MacroGenics, Inc. (MGNX) Downgraded to "Strong Sell" at ValuEngineMacroGenics, Inc. (MGNX) Downgraded to "Strong Sell" at ValuEngine
www.americanbankingnews.com - November 26 at 12:56 PM
MacroGenics, Inc. (MGNX) SVP Jon Marc Wigginton Sells 5,000 SharesMacroGenics, Inc. (MGNX) SVP Jon Marc Wigginton Sells 5,000 Shares
www.americanbankingnews.com - November 21 at 9:08 PM
Critical Contrast: MacroGenics (MGNX) vs. AcelRx Pharmaceuticals (ACRX)Critical Contrast: MacroGenics (MGNX) vs. AcelRx Pharmaceuticals (ACRX)
www.americanbankingnews.com - November 17 at 9:30 PM
MacroGenics Names Dr. Jay Siegel to its Board of DirectorsMacroGenics Names Dr. Jay Siegel to its Board of Directors
finance.yahoo.com - November 17 at 4:17 PM
MacroGenics, Inc. (MGNX) Expected to Announce Earnings of $1.60 Per ShareMacroGenics, Inc. (MGNX) Expected to Announce Earnings of $1.60 Per Share
www.americanbankingnews.com - November 14 at 1:28 AM
MacroGenics, Inc. breached its 50 day moving average in a Bullish Manner : MGNX-US : November 13, 2017MacroGenics, Inc. breached its 50 day moving average in a Bullish Manner : MGNX-US : November 13, 2017
finance.yahoo.com - November 13 at 4:40 PM
MacroGenics to Participate in Two Upcoming Investor ConferencesMacroGenics to Participate in Two Upcoming Investor Conferences
finance.yahoo.com - November 13 at 4:40 PM
MacroGenics, Inc. (MGNX) Expected to Post FY2017 Earnings of ($0.43) Per ShareMacroGenics, Inc. (MGNX) Expected to Post FY2017 Earnings of ($0.43) Per Share
www.americanbankingnews.com - November 13 at 2:58 AM
FY2017 Earnings Forecast for MacroGenics, Inc. (MGNX) Issued By Leerink SwannFY2017 Earnings Forecast for MacroGenics, Inc. (MGNX) Issued By Leerink Swann
www.americanbankingnews.com - November 13 at 2:58 AM
MacroGenics, Inc. (MGNX) PT Raised to $22.00 at Citigroup Inc.MacroGenics, Inc. (MGNX) PT Raised to $22.00 at Citigroup Inc.
www.americanbankingnews.com - November 12 at 8:39 AM
Edited Transcript of MGNX earnings conference call or presentation 8-Nov-17 9:30pm GMTEdited Transcript of MGNX earnings conference call or presentation 8-Nov-17 9:30pm GMT
finance.yahoo.com - November 12 at 6:45 AM
MacroGenics Announces Poster Presentations at 32nd Annual SITC Meeting 2017MacroGenics Announces Poster Presentations at 32nd Annual SITC Meeting 2017
finance.yahoo.com - November 12 at 6:45 AM
Analysts Offer Predictions for MacroGenics, Inc.s Q1 2018 Earnings (MGNX)Analysts Offer Predictions for MacroGenics, Inc.'s Q1 2018 Earnings (MGNX)
www.americanbankingnews.com - November 10 at 3:38 PM
MacroGenics, Inc. (MGNX) Issues  Earnings ResultsMacroGenics, Inc. (MGNX) Issues Earnings Results
www.americanbankingnews.com - November 9 at 7:48 PM
MacroGenics, Inc. to Host Earnings CallMacroGenics, Inc. to Host Earnings Call
finance.yahoo.com - November 8 at 6:02 PM
MacroGenics Provides Update on Corporate Progress and Third Quarter 2017 Financial ResultsMacroGenics Provides Update on Corporate Progress and Third Quarter 2017 Financial Results
finance.yahoo.com - November 8 at 6:02 PM
MacroGenics reports 3Q lossMacroGenics reports 3Q loss
finance.yahoo.com - November 8 at 6:02 PM
MacroGenics, Inc. (MGNX) to Release Quarterly Earnings on WednesdayMacroGenics, Inc. (MGNX) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - November 2 at 8:22 PM
MacroGenics to Present Phase 1 Data on Flotetuzumab, a CD123 x CD3 DART® Molecule, at 59th Annual ASH MeetingMacroGenics to Present Phase 1 Data on Flotetuzumab, a CD123 x CD3 DART® Molecule, at 59th Annual ASH Meeting
finance.yahoo.com - November 2 at 6:23 AM
MacroGenics Announces Date of Third Quarter 2017 Financial Results Conference CallMacroGenics Announces Date of Third Quarter 2017 Financial Results Conference Call
finance.yahoo.com - November 2 at 6:23 AM
MacroGenics, Inc. (MGNX) Given Average Recommendation of "Hold" by BrokeragesMacroGenics, Inc. (MGNX) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 1 at 3:40 PM
MacroGenics, Inc. (MGNX) SVP Sells $200,000.00 in StockMacroGenics, Inc. (MGNX) SVP Sells $200,000.00 in Stock
www.americanbankingnews.com - October 26 at 11:34 AM
$6.08 Million in Sales Expected for MacroGenics, Inc. (MGNX) This Quarter$6.08 Million in Sales Expected for MacroGenics, Inc. (MGNX) This Quarter
www.americanbankingnews.com - October 26 at 9:20 AM
Why MacroGenics, Inc. Stock Soared TodayWhy MacroGenics, Inc. Stock Soared Today
www.fool.com - October 25 at 6:56 PM
Incyte IINCY) and MacroGenics (MGNX) Enter Pact on Anti-PD-1 Monoclonal Antibody MGA012 - StreetInsider.comIncyte IINCY) and MacroGenics (MGNX) Enter Pact on Anti-PD-1 Monoclonal Antibody MGA012 - StreetInsider.com
www.streetinsider.com - October 25 at 7:15 AM
MacroGenics, Inc. breached its 50 day moving average in a Bearish Manner : MGNX-US : October 24, 2017MacroGenics, Inc. breached its 50 day moving average in a Bearish Manner : MGNX-US : October 24, 2017
finance.yahoo.com - October 25 at 7:15 AM
Incyte and MacroGenics Announce Global Collaboration and Licensing Agreement for Anti-PD-1 Monoclonal Antibody MGA012Incyte and MacroGenics Announce Global Collaboration and Licensing Agreement for Anti-PD-1 Monoclonal Antibody MGA012
finance.yahoo.com - October 25 at 7:14 AM
MacroGenics, Inc. (MGNX) Expected to Post Earnings of -$1.03 Per ShareMacroGenics, Inc. (MGNX) Expected to Post Earnings of -$1.03 Per Share
www.americanbankingnews.com - October 24 at 12:20 PM
MacroGenics, Inc. (MGNX) Set to Announce Quarterly Earnings on TuesdayMacroGenics, Inc. (MGNX) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 24 at 8:54 AM
MacroGenics, Inc. breached its 50 day moving average in a Bullish Manner : MGNX-US : October 13, 2017MacroGenics, Inc. breached its 50 day moving average in a Bullish Manner : MGNX-US : October 13, 2017
finance.yahoo.com - October 14 at 3:03 AM
MacroGenics, Inc. (MGNX) Given Consensus Recommendation of "Hold" by BrokeragesMacroGenics, Inc. (MGNX) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - October 7 at 4:34 PM
MacroGenics, Inc. (MGNX) Expected to Announce Quarterly Sales of $6.08 MillionMacroGenics, Inc. (MGNX) Expected to Announce Quarterly Sales of $6.08 Million
www.americanbankingnews.com - October 7 at 5:18 AM
 Brokerages Anticipate MacroGenics, Inc. (MGNX) Will Announce Earnings of -$1.03 Per Share Brokerages Anticipate MacroGenics, Inc. (MGNX) Will Announce Earnings of -$1.03 Per Share
www.americanbankingnews.com - October 5 at 4:48 PM
MacroGenics, Inc. – Value Analysis (NASDAQ:MGNX) : September 27, 2017MacroGenics, Inc. – Value Analysis (NASDAQ:MGNX) : September 27, 2017
finance.yahoo.com - October 2 at 11:54 AM
MacroGenics, Inc. breached its 50 day moving average in a Bullish Manner : MGNX-US : September 26, 2017MacroGenics, Inc. breached its 50 day moving average in a Bullish Manner : MGNX-US : September 26, 2017
finance.yahoo.com - September 26 at 9:06 AM
MacroGenics, Inc. (MGNX) Expected to Announce Earnings of -$1.03 Per ShareMacroGenics, Inc. (MGNX) Expected to Announce Earnings of -$1.03 Per Share
www.americanbankingnews.com - September 16 at 10:18 PM
MacroGenics, Inc. breached its 50 day moving average in a Bearish Manner : MGNX-US : September 13, 2017MacroGenics, Inc. breached its 50 day moving average in a Bearish Manner : MGNX-US : September 13, 2017
finance.yahoo.com - September 14 at 7:43 AM
MacroGenics, Inc. to Post FY2018 Earnings of ($4.24) Per Share, SunTrust Banks Forecasts (MGNX)MacroGenics, Inc. to Post FY2018 Earnings of ($4.24) Per Share, SunTrust Banks Forecasts (MGNX)
www.americanbankingnews.com - September 13 at 1:22 PM
Analyzing MacroGenics (MGNX) & Its RivalsAnalyzing MacroGenics (MGNX) & Its Rivals
www.americanbankingnews.com - September 13 at 12:38 AM

SEC Filings

MacroGenics (NASDAQ:MGNX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

MacroGenics (NASDAQ:MGNX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

MacroGenics (NASDAQ MGNX) Stock Chart for Saturday, December, 16, 2017

Loading chart…

This page was last updated on 12/16/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.